November 20, 2017 06:02 AM ESTUpdated 08:17 AM
People
R&D

Fear­less: Ju­lian Adams looks to steer Gami­da Cell through PhI­II, an IPO and a mar­ket launch

John Carroll

Editor & Founder

Ju­lian Adams be­came some­thing of a lo­cal leg­end in the Boston/Cam­bridge area when he helped dri­ve the de­vel­op­ment pro­gram for Vel­cade — a drug that helped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion

A service from the Financial Times